HealthCare Royalty Partners
HealthCare Royalty Partners is a global investment firm that partners with healthcare companies, non-profit institutions and inventors.
Business Model:
Revenue: $228.8M
Employees: 11-50
Rankings
Detailed HealthCare Royalty Partners Information
Geographic Data
Address: 300 Atlantic Street,
City: Stamford
State: CT
Zip: 06901
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$7B
Social
Linkedin
Crunchbase
Metrics
9,201,199Website Global Rank
190Website Monthly Traffic
Twitter Followers
Description
We are a $3.0+ billion global healthcare investment firm. We invest primarily in commercial stage healthcare product assets that have significant clinical value, strong barriers to entry and that are marketed by some of the world’s largest pharmaceutical companies. Over the past decade, our senior investment team has completed more than 60 royalty investments valued in excess of $2.5 billion. For more information, visit www.healthcareroyalty.com.
Contact Phone:
+12034878300
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 6/2022 | Rhythm Pharmaceuticals | Post-IPO Debt | 37.5M |
| 11/2014 | Helomics | Series E | 0 |
| 9/2014 | Cardiorentis | Series A | 58.1M |
| 1/2014 | Suneva Medical | Debt Financing | 15M |
| 9/2021 | Spero Therapeutics | Post-IPO Debt | 0 |
| 2/2014 | Nuron Biotech | Private Equity Round | 22.7M |
| 3/2019 | Portola Pharmaceuticals | Post-IPO Debt | 125M |
| 9/2014 | AcuFocus | Venture Round | 0 |
| 1/2014 | Suneva Medical | Series B | 20M |
| 4/2016 | TearScience | Series D | 0 |
| 2/2015 | Invuity | Equity | 22.9M |
| 8/2022 | Clearside Biomedical | Post-IPO Debt | 65M |
| 11/2011 | AcuFocus | Private Equity Round | 0 |
| 1/2023 | Liquidia Technologies | Post-IPO Debt | 32.5M |
| 2/2013 | TearScience | Private Equity Round | 70M |
| 1/2019 | Coherus Biosciences | Post-IPO Debt | 75M |
| 6/2022 | Ardelyx | Post-IPO Debt | 0 |
| 12/2012 | Nuron Biotech | Private Equity Round | 80M |
| 7/2014 | Raptor Pharmaceuticals | Post-IPO Debt | 70M |
| 3/2014 | Invuity | Series E | 36M |
| 6/2022 | Ardelyx | Post-IPO Debt | 0 |
| 6/2022 | Rhythm Pharmaceuticals | Post-IPO Debt | 0 |
| 9/2021 | Spero Therapeutics | Post-IPO Debt | 0 |
| 3/2019 | Portola Pharmaceuticals | Post-IPO Debt | 0 |
| 1/2019 | Coherus Biosciences | Post-IPO Debt | 0 |
| 4/2016 | TearScience | Series D | 0 |
| 2/2015 | Invuity | Private Equity Round | 0 |
| 11/2014 | Helomics | Series E | 0 |
| 9/2014 | Cardiorentis | Series A | 0 |
| 9/2014 | AcuFocus | Venture Round | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
